Adamas to Present at Upcoming Evercore ISI Conference
Adamas Pharmaceuticals (Nasdaq: ADMS) has announced that CEO Neil F. McFarlane will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 11:45 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adamas Pharmaceuticals (Nasdaq: ADMS) has announced that CEO Neil F. McFarlane will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 11:45 am ET. The presentation, aimed at discussing advancements in neurological disease treatments, will be webcast live from the investor relations section of the Adamas website. An archived version will be available for 30 days post-presentation. Adamas is focused on developing innovative medicines to alleviate the burden of neurological diseases.
Details
News Market Reaction – ADMS
The recorded move for ADMS in the trading session of this news was +1.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 am Eastern Time (8:45 am Pacific).
The presentation will be webcast from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. Archived versions of the webcast will be available via replay for 30 days following the presentation.
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.
Contact
Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com
Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.